UA106037C2 - Модулятори ampk (амф-активованої протеїнкінази) - Google Patents
Модулятори ampk (амф-активованої протеїнкінази)Info
- Publication number
- UA106037C2 UA106037C2 UAA201010653A UAA201010653A UA106037C2 UA 106037 C2 UA106037 C2 UA 106037C2 UA A201010653 A UAA201010653 A UA A201010653A UA A201010653 A UAA201010653 A UA A201010653A UA 106037 C2 UA106037 C2 UA 106037C2
- Authority
- UA
- Ukraine
- Prior art keywords
- ampk
- modulators
- protein kinase
- activated protein
- prodrugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Даний винахід стосується сполук і фармацевтично прийнятних солей, естерів і проліків формули (І) або (II), які можуть використовуватись як ефективні модулятори АМРК при лікуванні діабету, ожиріння і раку.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2600108P | 2008-02-04 | 2008-02-04 | |
US5120008P | 2008-05-07 | 2008-05-07 | |
PCT/US2009/033077 WO2009100130A1 (en) | 2008-02-04 | 2009-02-04 | Ampk modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
UA106037C2 true UA106037C2 (uk) | 2014-07-25 |
Family
ID=40952443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201010653A UA106037C2 (uk) | 2008-02-04 | 2009-02-04 | Модулятори ampk (амф-активованої протеїнкінази) |
Country Status (16)
Country | Link |
---|---|
US (3) | US8273744B2 (uk) |
EP (1) | EP2240016A4 (uk) |
JP (2) | JP5525456B2 (uk) |
KR (1) | KR20100115789A (uk) |
CN (1) | CN101959404B (uk) |
AU (1) | AU2009212462B2 (uk) |
BR (1) | BRPI0905952A2 (uk) |
CA (1) | CA2714181C (uk) |
EA (1) | EA019309B1 (uk) |
IL (1) | IL207234A (uk) |
MX (1) | MX2010008376A (uk) |
MY (1) | MY158994A (uk) |
NZ (1) | NZ587165A (uk) |
UA (1) | UA106037C2 (uk) |
WO (1) | WO2009100130A1 (uk) |
ZA (1) | ZA201005600B (uk) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007041643A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
EP3466953B1 (en) | 2005-12-13 | 2021-02-03 | Incyte Holdings Corporation | Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor |
SI2173752T2 (sl) | 2007-06-13 | 2022-09-30 | Incyte Holdings Corporation | Soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4- il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila |
EA019309B1 (ru) * | 2008-02-04 | 2014-02-28 | Меркьюри Терапьютикс, Инк. | Модуляторы ampk (амф-активируемой протеинкиназы) |
CN101998853B (zh) | 2008-04-11 | 2015-02-11 | 默克专利有限公司 | 作为amp-活化的蛋白激酶(ampk)激活剂的噻吩并吡啶酮衍生物 |
US8394969B2 (en) | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2009309007A1 (en) | 2008-10-29 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
MX2011012353A (es) | 2009-05-22 | 2011-12-14 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. |
AR076920A1 (es) | 2009-05-22 | 2011-07-20 | Incyte Corp | 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
GB0915892D0 (en) * | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
WO2011032320A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Novel alkene oxindole derivatives |
US8519134B2 (en) | 2009-11-17 | 2013-08-27 | Novartis Ag | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
AR081315A1 (es) | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
CN103002875B (zh) | 2010-05-21 | 2016-05-04 | 因塞特控股公司 | Jak抑制剂的局部用制剂 |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Npy y5受容体拮抗作用を有するヘテロ環誘導体 |
MX337714B (es) * | 2010-09-10 | 2016-03-16 | Shionogi & Co | Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk). |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
US8809369B2 (en) * | 2011-01-26 | 2014-08-19 | Hoffmann-La Roche Inc. | Tetrahydroquinoline derivatives |
CN103328449A (zh) * | 2011-01-26 | 2013-09-25 | 霍夫曼-拉罗奇有限公司 | 新的四氢喹啉衍生物 |
JP5728099B2 (ja) * | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体 |
US20130345243A1 (en) * | 2011-03-07 | 2013-12-26 | Glaxosmithkline Llc | 1h-pyrollo[3,2-d]pyrimidinedione derivatives |
KR101624020B1 (ko) | 2011-03-07 | 2016-05-24 | 글락소스미스클라인 엘엘씨 | 퀴놀리논 유도체 |
MX344479B (es) | 2011-06-20 | 2016-12-16 | Incyte Holdings Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak). |
BR112014001018A2 (pt) * | 2011-07-15 | 2017-01-10 | Shionogi & Co | derivado de azabenzimidazol tendo atividade de ativação de ampk |
BR112014000895A2 (pt) | 2011-07-15 | 2019-08-06 | Nusirt Sciences Inc | composições e métodos para modular rotas metabólicas |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US8889730B2 (en) * | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
TWI449702B (zh) * | 2012-07-11 | 2014-08-21 | Merck Sharp & Dohme | 作為抗糖尿病劑之新穎環氮雜苯并咪唑衍生物 |
BR112015010947A2 (pt) | 2012-11-13 | 2018-06-05 | Nusirt Sciences Inc | composições e métodos para aumentar o metabolismo energético. |
UA120834C2 (uk) | 2012-11-15 | 2020-02-25 | Інсайт Холдінгс Корпорейшн | Лікарські форми руксолітинібу зі сповільненим вивільненням |
EP2769974A1 (en) * | 2013-02-21 | 2014-08-27 | Debiopharm S.A. | Novel AMPK activator |
RS58547B1 (sr) | 2013-03-06 | 2019-05-31 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
WO2014139388A1 (en) * | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2970177A1 (en) * | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
MX2015011195A (es) | 2013-03-15 | 2016-03-11 | Nusirt Sciences Inc | La leucina y el acido nicotinico reducen los niveles de lipidos. |
WO2014175330A1 (ja) * | 2013-04-24 | 2014-10-30 | 塩野義製薬株式会社 | Ampk活性化作用を有する5-オキシベンズイミダゾールおよび5-オキシアザベンズイミダゾール誘導体 |
JP2016521761A (ja) * | 2013-06-20 | 2016-07-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ampk活性を有するオレフィン置換オキシインドール |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
AU2015222754B2 (en) | 2014-02-27 | 2020-06-25 | Nusirt Sciences Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
CA2959293A1 (en) | 2014-08-27 | 2016-03-03 | Shionogi & Co., Ltd. | Azaindole derivative having ampk-activating effect |
WO2016068099A1 (ja) | 2014-10-28 | 2016-05-06 | 塩野義製薬株式会社 | Ampk活性化作用を有する複素環誘導体 |
CN104774172B (zh) * | 2015-04-08 | 2017-03-22 | 河南师范大学 | 一种3‑氰基吲哚类化合物的合成方法 |
JP6607962B2 (ja) * | 2015-05-26 | 2019-11-20 | カオシュン メディカル ユニバーシティー | β−グルクロニダーゼの阻害のためのピラゾロ[4,3−c]キノリン誘導体 |
WO2017146186A1 (ja) | 2016-02-26 | 2017-08-31 | 塩野義製薬株式会社 | Ampk活性化作用を有する5-フェニルアザインドール誘導体 |
EP3459949A4 (en) | 2016-05-20 | 2020-04-08 | Shionogi & Co., Ltd | 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
EP3510032B1 (en) | 2016-09-09 | 2022-07-06 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
CN107556309B (zh) * | 2017-09-11 | 2020-12-01 | 浙江永宁药业股份有限公司 | 多取代四氢萘啶类化合物的药物用途及其制备方法 |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
JP7382348B2 (ja) | 2018-02-06 | 2023-11-16 | アイディアヤ バイオサイエンシーズ,インコーポレイティド | AhRモジュレータ |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
HRP20220833T1 (hr) | 2018-02-20 | 2022-10-28 | Incyte Corporation | Derivati n-(fenil)-2-(fenil)pirimidin-4-karboksamida i odgovarajući spojevi kao inhibitori hpk1 za liječenje raka |
MX2020009228A (es) | 2018-03-08 | 2021-01-08 | Incyte Corp | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. |
JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ2媒介性シグナル伝達の阻害剤 |
KR20210018203A (ko) | 2018-03-30 | 2021-02-17 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
AU2019336597B2 (en) * | 2018-08-06 | 2024-09-19 | Skylark Bioscience Llc | Amp-activated protein kinase activating compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
US11111247B2 (en) | 2018-09-25 | 2021-09-07 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
JP2022543155A (ja) | 2019-08-06 | 2022-10-07 | インサイト・コーポレイション | Hpk1阻害剤の固体形態 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN116322663A (zh) | 2020-09-30 | 2023-06-23 | 比奥维拉迪维治疗股份有限公司 | Ampk激活剂及其使用方法 |
CN112342216B (zh) * | 2020-11-13 | 2021-07-23 | 中国人民解放军军事科学院军事医学研究院 | 用于提高CHO细胞的表达效率的CRISPR-Cas13d系统以及重组CHO细胞 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245044A (en) * | 1991-10-30 | 1993-09-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Di(hydroxyphenyl)-benzimidazole monomers |
DE69726745T2 (de) * | 1996-07-31 | 2004-09-30 | Shionogi & Co., Ltd. | NEUE p-TERPHENYL VERBINDUNGEN |
US6232322B1 (en) * | 1998-05-12 | 2001-05-15 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
JP2000204091A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Suisan Kaisha Ltd | 新規ベンゾジオキソ―ル誘導体 |
US6265403B1 (en) * | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
AU2001287898A1 (en) * | 2000-09-22 | 2002-04-02 | Stephen Garland | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
US20030203959A1 (en) * | 2002-03-04 | 2003-10-30 | 4Sc Ag | Novel modulators of potassium channels |
UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
CA2509565A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
JP2006525366A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 複素環式カルボン酸置換基 |
US7119205B2 (en) * | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
JP4319223B2 (ja) | 2004-08-04 | 2009-08-26 | 明治製菓株式会社 | キノリン誘導体およびそれを有効成分として含んでなる殺虫剤 |
GB0424308D0 (en) * | 2004-11-03 | 2004-12-01 | Qinetiq Ltd | Compounds for use in liquid crystal devices |
AU2005307735A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Substituted amino acids as protein Tyrosine phosphatase inhibitors |
CA2586612C (en) * | 2004-11-18 | 2016-10-11 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2006080821A1 (en) | 2005-01-28 | 2006-08-03 | Daewoong Pharmaceutical Co., Ltd. | Novel benzoimidazole derivatives and pharmaceutical composition comprising the same |
WO2007019397A2 (en) | 2005-08-05 | 2007-02-15 | Genelabs Technologies, Inc. | 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus |
US8629285B2 (en) * | 2005-08-18 | 2014-01-14 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate HSP90 activity |
US8629147B2 (en) * | 2005-11-03 | 2014-01-14 | Chembridge Corporation | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
US7723345B2 (en) * | 2005-12-29 | 2010-05-25 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
WO2007084667A2 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
JP5112083B2 (ja) | 2006-02-03 | 2013-01-09 | Meiji Seikaファルマ株式会社 | 新規キノリン誘導体およびこれを有効成分として含有する農園芸用殺菌剤 |
US20070191371A1 (en) | 2006-02-14 | 2007-08-16 | Kalypsys, Inc. | Heterocyclic modulators of ppar |
ES2484042T3 (es) * | 2006-05-25 | 2014-08-08 | Synta Pharmaceuticals Corporation | Compuestos de triazol que modulan la actividad de HSP90 |
US8436022B2 (en) | 2006-07-11 | 2013-05-07 | Daewoong Pharmaceutical Co., Ltd. | Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same |
JP2009544664A (ja) * | 2006-07-28 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | 脂質キナーゼ阻害剤としての2,4−置換キナゾリン |
EA019309B1 (ru) * | 2008-02-04 | 2014-02-28 | Меркьюри Терапьютикс, Инк. | Модуляторы ampk (амф-активируемой протеинкиназы) |
-
2009
- 2009-02-04 EA EA201001257A patent/EA019309B1/ru not_active IP Right Cessation
- 2009-02-04 CN CN200980107550.0A patent/CN101959404B/zh not_active Expired - Fee Related
- 2009-02-04 WO PCT/US2009/033077 patent/WO2009100130A1/en active Application Filing
- 2009-02-04 AU AU2009212462A patent/AU2009212462B2/en not_active Ceased
- 2009-02-04 MY MYPI2010003586A patent/MY158994A/en unknown
- 2009-02-04 KR KR1020107019375A patent/KR20100115789A/ko not_active Application Discontinuation
- 2009-02-04 NZ NZ587165A patent/NZ587165A/en not_active IP Right Cessation
- 2009-02-04 JP JP2010545273A patent/JP5525456B2/ja not_active Expired - Fee Related
- 2009-02-04 MX MX2010008376A patent/MX2010008376A/es active IP Right Grant
- 2009-02-04 UA UAA201010653A patent/UA106037C2/uk unknown
- 2009-02-04 US US12/365,671 patent/US8273744B2/en not_active Expired - Fee Related
- 2009-02-04 EP EP09707948A patent/EP2240016A4/en not_active Withdrawn
- 2009-02-04 CA CA2714181A patent/CA2714181C/en not_active Expired - Fee Related
- 2009-02-04 BR BRPI0905952-0A patent/BRPI0905952A2/pt not_active IP Right Cessation
-
2010
- 2010-07-26 IL IL207234A patent/IL207234A/en not_active IP Right Cessation
- 2010-08-05 ZA ZA2010/05600A patent/ZA201005600B/en unknown
-
2012
- 2012-08-09 US US13/571,218 patent/US8980895B2/en not_active Expired - Fee Related
-
2013
- 2013-09-17 JP JP2013191655A patent/JP2014028828A/ja not_active Withdrawn
-
2015
- 2015-02-19 US US14/625,925 patent/US20150266892A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2010008376A (es) | 2011-02-22 |
MY158994A (en) | 2016-11-30 |
AU2009212462B2 (en) | 2012-09-13 |
KR20100115789A (ko) | 2010-10-28 |
CA2714181A1 (en) | 2009-08-13 |
NZ587165A (en) | 2012-03-30 |
IL207234A (en) | 2016-06-30 |
CN101959404B (zh) | 2015-12-02 |
ZA201005600B (en) | 2016-09-28 |
JP5525456B2 (ja) | 2014-06-18 |
EA019309B1 (ru) | 2014-02-28 |
BRPI0905952A2 (pt) | 2015-06-30 |
JP2014028828A (ja) | 2014-02-13 |
EA201001257A1 (ru) | 2011-04-29 |
JP2011511008A (ja) | 2011-04-07 |
US8980895B2 (en) | 2015-03-17 |
EP2240016A4 (en) | 2011-11-16 |
IL207234A0 (en) | 2010-12-30 |
US20150266892A1 (en) | 2015-09-24 |
CA2714181C (en) | 2013-12-24 |
US8273744B2 (en) | 2012-09-25 |
CN101959404A (zh) | 2011-01-26 |
WO2009100130A1 (en) | 2009-08-13 |
US20120302576A1 (en) | 2012-11-29 |
US20100009992A1 (en) | 2010-01-14 |
AU2009212462A1 (en) | 2009-08-13 |
EP2240016A1 (en) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA106037C2 (uk) | Модулятори ampk (амф-активованої протеїнкінази) | |
TN2011000291A1 (en) | Purine compounds | |
MX2012007098A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
MX2012007161A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
MX2011013176A (es) | Motivos de modificación química para inhibidores y miméticos del miarn. | |
WO2009152356A3 (en) | Compounds and compositions useful for the treatment of malaria | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
WO2012025213A3 (en) | Novel therapeutic compounds | |
MY156274A (en) | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | |
MX353308B (es) | Derivados fosforosos como inhibidores de cinasa. | |
TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
WO2008070268A3 (en) | Pharmaceutical compositions | |
MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
EA201270728A1 (ru) | Пуриновые соединения | |
IL206881A0 (en) | Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy | |
IL211189A0 (en) | Compounds for the treatment of peripheral neuropathies | |
MX2010002032A (es) | Uso de flibanserina para el tratamiento de sintomas vasomotores. | |
TW200800993A (en) | Organic compounds | |
ZA201009063B (en) | Diaryl ureas for treating heart failure | |
DE602008002598D1 (en) | Cyclohexylderivate | |
WO2011000945A3 (en) | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns | |
ZA201002576B (en) | Novel composition for treating the side effects of anticancer treatments |